• ECR Podcast - Ep 6: Inflammatory Biomarkers and Cardiovascular Risk

    What are the clinical challenges in the use of biomarkers to estimate the risk of a cardiovascular event?

  • Targeting Inflammation in Atherosclerosis: Current Guidelines and Clinical Data

    Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Dr Aernoud Fiolet (University Medical Center Utrecht, Netherlands) as they explore topics such as how guidelines currently view anti-inflammatory approaches and main molecules under investigation.

    Supported by an unrestricted educational grant from NOVO NORDISK A/S.

  • Targeting Inflammation in Atherosclerosis: Inflammation and Atherosclerosis

    Inflammation and Atherosclerosis – What is the Link with CKD? Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Lina Badimon (Hospital of Santa Creu and San Pau, Barcelona, Spain) as they discuss that very question.

    Supported by an unrestricted educational grant from NOVO NORDISK A/S.

  • Targeting Inflammation in Atherosclerosis: Therapeutic Targets and Mode of Action

    Prof Juan Carlos Kaski (St George’s University of London, UK) alongside Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) provide us with a short and concise discussion regarding Therapeutic Targets and Mode of Action.

    Supported by an unrestricted educational grant from NOVO NORDISK A/S.

  • Targeting Inflammation in Atherosclerosis: Inflammatory Signalling in Atherosclerosis and CKD

    Inflammatory Signalling in Atherosclerosis and CKD is the topic of interest in this short peer to peer discussion involving Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US).

    Supported by an unrestricted educational grant from NOVO NORDISK A/S.

  • Targeting Inflammation in Atherosclerosis: Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease

    Prof Juan Carlos Kaski (St George’s University of London, UK) is joined by Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) to discuss Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease where they cover topics such as elevated hsCRP and chronic kidney disease. Supported by an unrestricted educational grant from NOVO NORDISK A/S.

  • Targeting Inflammation in Atherosclerosis: COLCOT Trial

    Prof Jean-Claude Tardif (Montreal Heart Institute, Canada) gives us a comprehensive overview of the COLCOT trial.

    Supported by an unrestricted educational grant from NOVO NORDISK A/S.

  • Targeting Inflammation in Atherosclerosis: LoDoCo2 Trial

    In this LoDoCo2 presentation, Dr Aernoud Fiolet (University Medical Center Utrecht, Netherlands) covers the trial design and main results.

    Supported by an unrestricted educational grant from NOVO NORDISK A/S.

  • Targeting Inflammation in Atherosclerosis: RESCUE Trial

    Join Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) as he talks us through the RESCUE trial design and results in this short podcast.

  • Targeting Inflammation in Atherosclerosis: CANTOS Trial

    Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) provides us with an overview of the CANTOS main trial results and updated results from the ACC 2022.

  • ECR Podcast - Ep 5: Invasive Diagnosis of Coronary Functional Disorders Causing Angina Pectoris

    Did you know that coronary vasomotion disorders are a frequent cause of angina in patients with non-obstructed coronary arteries? In this month's episode of the ECR podcast, Dr Andreas Seitz and Dr Peter Ong (Robert-Bosch Hospital, Stuttgart, DE) return to discuss their recent article on the diagnosis of coronary disorders which cause angina (https://www.ecrjournal.com/articles/invasive-diagnosis-coronary-functional-disorders-causing-angina-pectoris) from ECR Journal.

  • ECR Podcast - Ep 4: The EXCEL Trial: The Interventionalists’ Perspective

    In this month's featured author episode of the ECR Podcast, interventional fellow Dr George Hunter (Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK) discusses the EXCEL trial from his perspective as a member of the PCI community, based on a recent review paper from the ECR Journal. In this podcast, Dr Hunter discusses the controversy surrounding the trial and the importance of studying left main stem disease in cardiology today.

  • Ep 3: Atrial Fibrillation in Congenital Heart Disease

    Did you know that atrial arrhythmias are the most common complication in adults with congenital heart disease?

    Dr Irene Martin de Miguel (Hospital General Universitario Gregorio Marañón, Madrid, Spain) joins us in this featured author episode to outline her recent review article, Atrial Fibrillation in Congenital Heart Disease. In this podcast, Dr de Miguel provides an overview of the current knowledge of AF in CHD, giving practical recommendations for your everyday practice.

  • Ep 2: Prognostication of patients with coronary stenoses: pre-and post-PCI

    Is there enough evidence to support the prognostic value of coronary physiology measurements in pre-and post-PCI settings? Is post-PCI FFR ready for clinical practice?

    Today's episode features co-hosts Dr Peter Ong and Dr Andreas Seitz (Robert-Bosch Hospital, Stuttgart, DE) who together summarise the main results from the TARGET FFR and DEFINE-FLOW trials that were presented at TCT Connect 2020 and published recently in ECR journal, in the context of the existing literature.

  • Ep 1: Women and Heart Disease

    Did you know that CV disease is the leading cause of death in women and that women are more likely to die of heart disease compared to men? Dr Erin Michos (John Hopkins Uni, US) and Dr Martha Gulati (Uni of Arizona, US) join us on the inaugural episode of the ECR podcast series to discuss issues surrounding women in heart disease. Together they explore a variety of topics that are addressed in the latest special focus issue in the European cardiology Review journal.